Trial Profile
Impact on the efficacy and safety of two target trough concentrations of Advagraf between 4 and 12 months post-transplantation in de novo renal transplant patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2016
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms ADEQUATE
- 09 Nov 2016 Status changed from active, no longer recruiting to completed according to the results published in the American Journal of Transplantation.
- 09 Nov 2016 Results published in the American Journal of Transplantation
- 07 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.